23:09 , Apr 6, 2018 |  BioCentury  |  Finance

Fundamentally driven

Continued struggles by the mega-cap bellwethers and the resurgence of volatility in global equity markets were the major themes of 1Q18, whipsawing biotech stocks throughout the quarter but leaving index values little changed on the...
17:46 , Apr 6, 2018 |  BC Week In Review  |  Clinical News

Aradigm's Linhaliq under EMA review for lung infection

Aradigm Corp. (NASDAQ:ARDM) said EMA accepted for review an MAA for Linhaliq liposomal ciprofloxacin to treat non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic Pseudomonas aeruginosa lung infections. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights...
18:55 , Apr 5, 2018 |  BC Extra  |  Company News

Aradigm's Linhaliq under EMA review for lung infection

Aradigm Corp. (NASDAQ:ARDM) said EMA accepted for review an MAA for Linhaliq liposomal ciprofloxacin to treat non-cystic fibrosis bronchiectasis (NCFBE) patients with chronic Pseudomonas aeruginosa lung infections. Grifols S.A. (Madrid:GRF; NASDAQ:GRFS) has exclusive, worldwide rights...
21:58 , Feb 14, 2018 |  BC Extra  |  Company News

Aradigm execs resign weeks after CRL

Aradigm Corp. (NASDAQ:ARDM) said President and CEO Igor Gonda, CMO Juergen Froehlich and CFO and VP of Finance Nancy Pecota resigned on Feb. 11, according to an SEC filing. The company named Chairman John Siebert...
20:12 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Aradigm gets CRL for Linhaliq

Aradigm Corp. (NASDAQ:ARDM) said FDA issued a complete response letter (CRL) for Linhaliq liposomal ciprofloxacin (ARD-3150) to treat non-cystic fibrosis bronchiectasis in patients with chronic Pseudomonas aeruginosa lung infections. The company says it plans to...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
21:33 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

Aradigm's Linhaliq gets PDUFA date

Aradigm Corp. (NASDAQ:ARDM) said FDA accepted and granted Priority Review to an NDA for Linhaliq liposomal ciprofloxacin (ARD-3150) to treat non-cystic fibrosis bronchiectasis (NCFBE) in patients with chronic Pseudomonas aeruginosa infections. Its PDUFA date is...
21:38 , Sep 25, 2017 |  BC Extra  |  Company News

Aradigm's Linhaliq gets PDUFA date

Aradigm Corp. (NASDAQ:ARDM) gained $0.83 (33%) to $3.36 on Monday after FDA accepted and granted Priority Review to an NDA for Linhaliq liposomal ciprofloxacin (ARD-3150) to treat non-cystic fibrosis bronchiectasis (NCFBE) in patients with chronic...
20:24 , Feb 16, 2017 |  BC Week In Review  |  Clinical News

Pulmaquin: Ph III ORBIT-3 and ORBIT-4 data

In December, Aradigm reported mixed data from the identical, 48-week, double-blind, international Phase III ORBIT-3 and ORBIT-4 trials of Pulmaquin in patients with non-CF bronchiectasis who have chronic P. aeruginosa lung infections. Top-line data from...
07:00 , May 2, 2016 |  BC Week In Review  |  Financial News

Aradigm completes private placement of senior convertible notes

Aradigm Corp. (NASDAQ:ARDM), Hayward, Calif.   Business: Drug delivery, Pulmonary   Date completed: 2016-04-22   Type: Private placement of senior convertible notes   Raised: $23 million   Shares outstanding prior: 14.8 million   Note: The...